Status:
COMPLETED
Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A
Lead Sponsor:
Yooyoung Pharmaceutical Co., Ltd.
Conditions:
Dyslipidemias
Eligibility:
MALE
19+ years
Phase:
PHASE1
Brief Summary
To evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A
Detailed Description
Phase 1 to evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A. Which is designed as two cohort, single-sequence, paralle, open label, multiple oral dosing.
Eligibility Criteria
Inclusion
- Over 19 ages healty men
- Over 50.0kg, 18.0kg/m2 ≤ BMI ≤30.0kg/m2
- Men who dont have congenital disease and other cronic disease need to be cared etc.
Exclusion
- Men who have congenital liver disease (AST, ALT, CK ≥ 2X ULN)
- Men who have drunken or eatten something including carffeine within 24 hours before etc.
Key Trial Info
Start Date :
November 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 23 2020
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04874142
Start Date
November 20 2019
End Date
March 23 2020
Last Update
May 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ChungBuk National University Hospital
Cheongju-si, South Korea